1DROP has partnered with the International Space Station U.S. National Laboratory (ISS National Lab) managed by the Center for the Advancement of Science in Space (CASIS), to collaborate on lab on a chip technology for medical diagnostics on the International Space Station. This will be the first experiment of capillary-driven microfluidics in space. The mission will demonstrate capillary flow control in microstructures, particle focusing, plasma separation, and will be quantified using fluorescent biochemical reactions.
SpaceX’s 20th commercial resupply service mission (SpaceX CRS-20) for NASA, a Dragon spacecraft on a Falcon 9 rocket, is scheduled to launch on Friday, March 6, 2020, from Florida’s Space Coast. Liftoff is set for 23:50 EST from Space Launch Complex 40 at the Cape Canaveral Air Force Station. The spacecraft will carry 1DROP devices to the ISS.
The Dragon spacecraft will carry more than 2 540 kilograms of science equipment, food and supplies for the six-person Expedition 62 crew on the ISS. Besides 1DROP’s science payload, the spacecraft will carry a variety of space experiments “including research on particle foam manufacturing, water droplet formation, the human intestine and other cutting-edge investigations.”
1DROP is a portable medical diagnostics device currently capable of detecting biomarkers of cardiovascular health, liver and kidney function from a single drop of sample with laboratory quality results. Dr. Luc Gervais commented: “The ISS and space are the ultimate remote setting to demonstrate medical diagnostics. If 1DROP is suited to assess the health of astronauts in space, it’s suited to assess people’s health everywhere on earth. We are also currently developing 1DROP for long-duration space missions to Mars.”
We are committed to improving people’s lives by enabling precision medicine through non-invasive diagnostic tests. We provide actionable health information that is accessible everywhere. 1DROP facilitates the early detection, prevention and management of disease and empowers people to live better lives. 1DROP’s innovative diagnostic solutions for multiplexed assays of proteins, nucleic acids and peptides serve as tools for the development of new therapies, disease research, and clinical diagnostic tests. The company is based in Boston, United States and Neuchatel, Switzerland.
For more information, visit www.1dropdx.com
Press Contact :
Founder and CEO, 1DROP